TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04379284

Intervention type: OTHER
Intervention: Biospecimen collection
Description: Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.~Neonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab.

Intervention type: OTHER
Intervention: Biospecimen collection
Description: Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.~Neonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab.
Study: NCT03211351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposic
Description: one eye of the participant recieved Lipoic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: the other eye of the participant recieved Tears Naturale Forte
Study: NCT00597428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg capsules twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mcg capsules twice daily (BID)
Study: NCT03828409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long stitch
Description: Long stitch uses a larger needle and suture material. The suture is placed 1cm from the linea alba and 1 cm from previous suture. This technique include mass closure sutures at the midline laparotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long stitch
Description: Long stitch uses a larger needle and suture material. The suture is placed 1cm from the linea alba and 1 cm from previous suture. This technique include mass closure sutures at the midline laparotomy
Study: NCT01776047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exforge®
Study: NCT02118025

Intervention type: PROCEDURE
Intervention: Off-pump coronary artery bypass graft
Description: Patients operated with the heart beating, without heart arrest.

Intervention type: PROCEDURE
Intervention: Mini extracorporeal circulation bypass
Description: Patients operated with a modified extracorporeal circulation system
Study: NCT03837171

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Red blood cell transfusion
Description: Hemoglobin level will be maintained above 9 g/dL (liberal strategy) for the first 48 hours following randomization. After 48 hours, indications of RBC transfusions will be at the discretion of attending physicians in patients with persistent circulatory failure.~After resolution of acute circulatory failure, a 7 g/dL transfusion threshold will be recommended regardless of the allocation arm. In case of subsequent episodes of septic shock, the transfusion strategy will be at the discretion of attending physicians

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Restrictive Red blood cell transfusion
Description: Hemoglobin level will be maintained above 7 g/dL (restrictive strategy) during all the stay in ICU
Study: NCT04618939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BR-TD-1001
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td-pur inj
Description: 0.5 mL, IM
Study: NCT02203578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03385954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The distance eduacation group course has a workload of 8 hours and will be developed over 2 weeks. It is suggested that students have a minimum of 1 hour of study per day. The course will consist of work tips, clarifications and procedures for the prevention of RIS/WRMD physical training tips to improve cardiovascular condition and, of strength and flexibility, available literature and theoretical evidence that should be answered through the knowledge acquired in the EAD course of prevention of LERDORT from the HCPA's Physiatrics and Rehabilitation Service. This Course will be available through moodle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: will receive a lecture of 30 minutes.
Study: NCT04018690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patients will be submitted to needle lavage, followed by the injection of 3mL of hylan and 1 mL of ropivacaine
Description: Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine,
Description: Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis.
Study: NCT01932190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early RRT strategy
Description: the early strategy : RRT is started immediately when a RIFLE F status is documented

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed RRT strategy
Description: The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria: see summary
Study: NCT01263561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ExPRESS shunt
Description: ExPRESS miniature glaucoma drainage device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trabeculectomy
Description: trabeculectomy filtering surgery
Study: NCT03354208

Intervention type: OTHER
Intervention: blood sampling
Description: small volume blood sampling, according to local laws, is not categorized as intervention (observational study)

Intervention type: OTHER
Intervention: blood sampling
Description: small volume blood sampling, according to local laws, is not categorized as intervention (observational study)

Intervention type: OTHER
Intervention: blood sampling
Description: small volume blood sampling, according to local laws, is not categorized as intervention (observational study)
Study: NCT01897441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02659371

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low energy diet
Study: NCT01897441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study: NCT01776047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-0081
Study: NCT02645721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended self-help program with guidance
Description: See arm description for Experimental

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Briefer Self-help program, no guidance
Description: See arm description for Active Comparator

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WL: Extended self-help program, choice of guidance intensity
Description: See arm description for Waiting list.
Study: NCT03031158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFEX+H
Description: Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SFEX
Description: Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
Study: NCT02565459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Study: NCT03783975

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Simplified Cascade Screening
Description: Screening of the KCNQ1 Thr224Met variant for family members of probands
Study: NCT03130491

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Description: placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement

Intervention type: DEVICE
Group type: OTHER
Intervention: EMBLOK filter
Description: Embolic Filter Protection System During TAVR
Study: NCT04738409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The purpose of the research is to evaluate the potential of a multidimensional lifestyle program for PCOS girls. The primary aim is to verify the effectiveness of a 16-week AID intervention vs. HCD (combined with PA\&T), in terms of improvement in androgens level and immune-metabolic risk parameters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The purpose of the research is to evaluate the potential of a multidimensional lifestyle program for PCOS girls. The primary aim is to verify the effectiveness of a 16-week AID intervention vs. HCD (combined with PA\&T), in terms of improvement in androgens level and immune-metabolic risk parameters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls
Description: The purpose of the intervention is to evaluate the effectiveness of the anti-inflammatory diet (AIDiet) among normal weight (N) and overweight/obese (Ov/Ob) women with PCOS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls
Description: The purpose of the intervention is to evaluate the effectiveness of the anti-inflammatory diet (AIDiet) among normal weight (N) and overweight/obese (Ov/Ob) women with PCOS.
Study: NCT00487682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: oral
Study: NCT02498613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-Fluoromisonidazole
Description: Correlative studies
Study: NCT00487682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir hydrochloride
Description: oral
Study: NCT03316339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Opioid-free anesthesia
Study: NCT02498613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study: NCT03316339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Opioid anesthesia
Study: NCT04609969

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RT-qPCR test
Description: Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
Study: NCT01897441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study: NCT04609969

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-VIRO® test
Description: Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
Study: NCT04336410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.
Study: NCT02498613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03181984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoporfin
Description: Hemoporfin mediated photodynamic therapy
Study: NCT03756961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The intervention group will obtain the pharmacological treatment during both perioperative. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC)
Description: The intervention tests non-pharmacological interventions compared to conventional treatment, supplemented by an evidenced-based Person-centred care PCC approach throughout the continuum of the perioperative and until 4 weeks after discharge. This will be part of patients in Phase 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
Study: NCT01501396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Study: NCT03756961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulation (TENS)
Description: The intervention group will obtain non-pharmacological treatment by TENS during the entire hospital stay (both perioperative and post-operative) until discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
Study: NCT01501396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Study: NCT02714907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortrium C3 device
Description: Data is read from Cortrium C3 monitor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortrium C3 device
Description: Data is read from Cortrium C3 monitor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter device
Description: Date is read from Holter device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter device
Description: Date is read from Holter device
Study: NCT03339687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Mindset Induction
Description: This induction of a psychological state was extensively studied in cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list positive and negative, short- and long-term consequences of both deciding to act and not to act; indicating the probability of the occurrence of each of these consequences is required.~The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Mindset Induction
Description: This induction of a psychological state was extensively studied in cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list positive and negative, short- and long-term consequences of both deciding to act and not to act; indicating the probability of the occurrence of each of these consequences is required.~The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps.
Study: NCT01986907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
Study: NCT00810693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: BAY63-2521: 1.5mg tid orally for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tid orally for 12 weeks
Study: NCT01209923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BC1
Description: Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
Study: NCT02409212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo surveillance and written exercise guidelines
Description: Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
Study: NCT02069132

Intervention type: DRUG
Intervention: Warfarin
Description: warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.